126 related articles for article (PubMed ID: 15481937)
1. [Genomics and gene engineering: rationale to the development of new means of tuberculosis control].
Kariagina AS; Naroditskiĭ BS; Apt AS; Gintsburg AL
Zh Mikrobiol Epidemiol Immunobiol; 2004; (4):94-101. PubMed ID: 15481937
[TBL] [Abstract][Full Text] [Related]
2. Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?
Guapillo C; Hernández-Pando R; Flores-Valdez MA
Hum Vaccin Immunother; 2016 May; 12(5):1193-5. PubMed ID: 27049797
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.
Bivas-Benita M; Lin MY; Bal SM; van Meijgaarden KE; Franken KL; Friggen AH; Junginger HE; Borchard G; Klein MR; Ottenhoff TH
Vaccine; 2009 Jun; 27(30):4010-7. PubMed ID: 19389445
[TBL] [Abstract][Full Text] [Related]
4. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST
J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250
[TBL] [Abstract][Full Text] [Related]
5. Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice.
Cai H; Hu XD; Yu DH; Li SX; Tian X; Zhu YX
Vaccine; 2005 Jul; 23(32):4167-74. PubMed ID: 15908060
[TBL] [Abstract][Full Text] [Related]
6. Vaccine potential of Mycobacterium tuberculosis-specific genomic regions: in vitro studies in humans.
Mustafa AS
Expert Rev Vaccines; 2009 Oct; 8(10):1309-12. PubMed ID: 19803751
[No Abstract] [Full Text] [Related]
7. New hope for tuberculosis vaccines.
Olesen OF; Abdullah F; Coppens R; Gardner PJ; Ginsberg AM; Hanekom WA; Laang H; Lewinsohn DM; Loots G; Schmidt A; Vekemans J; Voss GH
Lancet Infect Dis; 2019 Jul; 19(7):687-688. PubMed ID: 31250810
[No Abstract] [Full Text] [Related]
8. A subunit vaccine based on biodegradable microspheres carrying rHsp65 protein and KLK protects BALB/c mice against tuberculosis infection.
dos Santos SA; Zárate-Bladés CR; de Sá Galetti FC; Brandão IT; Masson AP; Soares EG; Araújo AP; Silva CL
Hum Vaccin; 2010 Dec; 6(12):1047-53. PubMed ID: 21157178
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection.
Zhu D; Jiang S; Luo X
Vaccine; 2005 Aug; 23(37):4619-24. PubMed ID: 16053938
[TBL] [Abstract][Full Text] [Related]
10. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination.
Ha SJ; Park SH; Kim HJ; Kim SC; Kang HJ; Lee EG; Kwon SG; Kim BM; Lee SH; Kim WB; Sung YC; Cho SN
Infect Immun; 2006 Aug; 74(8):4954-9. PubMed ID: 16861689
[TBL] [Abstract][Full Text] [Related]
12. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.
Wozniak TM; Ryan AA; Triccas JA; Britton WJ
Infect Immun; 2006 Jan; 74(1):557-65. PubMed ID: 16369012
[TBL] [Abstract][Full Text] [Related]
13. Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis.
Vipond J; Clark SO; Hatch GJ; Vipond R; Marie Agger E; Tree JA; Williams A; Marsh PD
Tuberculosis (Edinb); 2006; 86(3-4):218-24. PubMed ID: 16520093
[TBL] [Abstract][Full Text] [Related]
14. Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli.
Brun P; Zumbo A; Castagliuolo I; Delogu G; Manfrin F; Sali M; Fadda G; Grillot-Courvalin C; Palù G; Manganelli R
Vaccine; 2008 Apr; 26(16):1934-41. PubMed ID: 18342411
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches to tuberculosis prevention: DNA vaccines.
Rivas-Santiago B; Cervantes-Villagrana AR
Scand J Infect Dis; 2014 Mar; 46(3):161-8. PubMed ID: 24450840
[TBL] [Abstract][Full Text] [Related]
16. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design.
Karbalaei Zadeh Babaki M; Soleimanpour S; Rezaee SA
Microb Pathog; 2017 Nov; 112():20-29. PubMed ID: 28942172
[TBL] [Abstract][Full Text] [Related]
17. Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines.
Khademi F; Taheri RA; Momtazi-Borojeni AA; Farnoosh G; Johnston TP; Sahebkar A
Rev Physiol Biochem Pharmacol; 2018; 175():47-69. PubMed ID: 29700609
[TBL] [Abstract][Full Text] [Related]
18. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model.
Fan X; Gao Q; Fu R
Microbiol Res; 2009; 164(4):374-82. PubMed ID: 17764918
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection.
Parlane NA; Compton BJ; Hayman CM; Painter GF; Basaraba RJ; Heiser A; Buddle BM
Vaccine; 2012 Jan; 30(3):580-8. PubMed ID: 22120192
[TBL] [Abstract][Full Text] [Related]
20. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?
Khademi F; Derakhshan M; Yousefi-Avarvand A; Tafaghodi M; Soleimanpour S
Expert Rev Vaccines; 2018 Jan; 17(1):31-44. PubMed ID: 29148853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
